Dubai Medical Team Reduces Diagnosis Time for Severe Pediatric Rare Diseases to Three Days Using Rapid Whole-Genome Sequencing
Background
Rare genetic diseases are a leading cause of infant mortality. Particularly for critically ill neonates in the Neonatal Intensive Care Unit (NICU) and pediatric patients in the Pediatric Intensive Care Unit (PICU), it is essential to rapidly identify the underlying cause of symptoms in order to prescribe personalized treatment. Conventional genetic testing often took weeks to months to yield results, frequently causing delays in treatment. These methods had limitations in terms of speed and accuracy, as they sequentially analyzed specific gene panels or single genes. At the same time, the Middle Eastern and Asian populations constitute a relatively small proportion of global genomic databases. Applying conventional reference genome-based diagnostic methods to Middle Eastern patients often leads to difficulty in identifying disease-causing variants or inaccurate results. As a result, the Middle East, a region with a diverse multinational population, has actively pursued the adoption of high-speed diagnostic systems that reflect the unique genetic backgrounds of its people.
Key Findings
Researchers at the Genomics Excellence Center at Al Jalila Children's Specialty Hospital developed and implemented a rapid whole-genome sequencing (rWGS) program called Little Falcon, and published results from its large-scale clinical application. This study focused on 100 critically ill neonatal and pediatric patients admitted under the Dubai Health System. The patients originated from 18 countries across the Middle East and Asia, representing diverse genetic backgrounds. The research team adopted a trio rWGS approach, analyzing the genomes of the patient along with those of their parents, to maximize the speed and accuracy of variant identification. Clinical implementation results showed that the Little Falcon program significantly reduced the average time to deliver genetic test results to 3.4 days. This is a remarkably faster speed compared to conventional methods, which often required several weeks. The overall diagnostic yield reached 53 percent. In patients from consanguineous families or those suspected of having metabolic disorders, the diagnostic yield increased to as high as 80 percent. Such rapid genetic insights have become a crucial key to changing patient care pathways in real-world clinical settings. In 53 percent of diagnosed patients, treatment strategies were altered, including medication changes, surgical interventions, and prognosis assessments. Ahmad Abou Tayoun, the lead researcher, explained that the diagnostic process was standardized using sequencing technology from the global genomics company Illumina.
Significance and Outlook
This study holds academic significance as it successfully implemented a city-wide rWGS system for the first time in the Middle East. Particularly, it provides a foundation for developing patient-specific diagnostic criteria tailored to Middle Eastern and Asian populations, moving away from Western-centric genomic data. With improved speed in genetic analysis, it is widely anticipated that this will accelerate a paradigm shift in critical care, enabling precision medicine based on genetic diagnostic results rather than relying on empirical treatment. However, there are still challenges to overcome before this diagnostic system is fully adopted in clinical practice. The high cost of equipment required for rWGS analysis and the need for trained personnel pose barriers to adoption, especially in countries with limited healthcare budgets. The development of information technology (IT) infrastructure for real-time storage and interpretation of large-scale genetic data, as well as regulatory frameworks, remains a pending task.
Nature Medicine, Published online: 27 August 2026; doi:10.1038/s41591-026-04627-9We describe the large-scale implementation of Little Falcon, a rapid whole-genome sequencing (rWGS) program that enables improved diagnosis and management of critically ill pediatric patients in Dubai. Our study demonstrates the clinical utility of rWGS in populations of Middle Eastern and Asian ancestries.
The achievements of the Little Falcon program are expected to serve as a practical tool for maximizing the survival rate of neonates with rare diseases in emergency situations. For example, in a specific scenario, when a neonate with acute respiratory distress or unexplained metabolic abnormalities is admitted to the NICU, medical staff can immediately request trio rWGS. Within three days, the genetic cause can be identified, preventing unnecessary experimental treatments and medication misuse due to misdiagnosis. In cases of specific enzyme deficiencies, targeted enzyme replacement therapy can be rapidly administered to prevent permanent organ damage. The pharmaceutical industry can also optimize the development of drugs targeting rare diseases by securing unique genomic diagnostic data from the Middle East. This will serve as a valuable milestone for selecting patient groups with rare variants, designing precision clinical trials, and significantly shortening the development period for customized therapies targeting specific genotypes.